Oramed Pharmaceuticals CFO Avraham Gabay sells $90,200 in stock

Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), sold 20,000 shares of the company’s common stock on October 1, 2026. The total value of the shares sold amounted to $90,200.

The shares were sold at a weighted average price of $4.51, with individual transaction prices ranging from $4.440 to $4.650. The transaction was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Gabay adopted on March 30, 2026. Following this sale, Mr. Gabay directly holds 861,076 shares of Oramed Pharmaceuticals common stock.The insider sale comes as Oramed shares have delivered strong returns, climbing 92% over the past year and gaining 31% in the last six months. The stock currently trades at $4.49 with a market capitalization of $184.69 million. According to InvestingPro analysis, the stock appears undervalued at current levels, and the company offers a dividend yield of 5.58%. Investors seeking deeper insights can access 10 additional InvestingPro Tips, along with comprehensive financial metrics and Fair Value analysis.

In other recent news, Oramed Pharmaceuticals Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved all six proposals presented. The meeting resulted in the re-election of directors Dr. Daniel Aghion, Dr. Miriam Kidron, Nadav Kidron, Dr. Arie Mayer, Yehuda Reznick, and Benjamin Shapiro. The directors will serve until the next annual meeting or until successors are elected. Vote tallies showed a range of 11,567,510 to 13,702,335 in favor, with between 3,729,485 and 5,859,953 votes against. This development underscores the continued support from shareholders for the company’s current leadership and strategic direction.